Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.


Updates from The Motley Fool

Latest updates on Ligand Pharmaceuticals from Fool.com.  The Fool has written over 100 articles on Ligand Pharmaceuticals.
3 Growth Stocks to Buy in June

If you're going to pay a hefty premium for a stock, it better have exceptional growth prospects. ...

5 Growth Stocks to Buy in March

Facebook is one of our contributor's picks. Image source: Facebook. Following the market's Januar...

The Best Value Stocks of 2015

Adios, 2015. Hello, 2016! For many investors, 2015 was a year of mixed emotions. The Federal Rese...



Stock Performance

View Interactive LGND Charts
Sponsored by

Key Data Points

Primary metrics and data points about Ligand Pharmaceuticals.
Current Price: $102.03
Prev Close: $101.46
Open: $101.50
Bid: $100.00
Ask: $101.00
Day's Range: $100.64 - $102.13
52wk Range: $82.06 - $139.79
Volume: 291,469
Avg Vol 298,285
Market Cap: $2B
P/E (ttm): 64.62
EPS (ttm): $1.57
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Ligand Pharmaceuticals.
CAPS Rating 3 out of 5
 
185 Outperform
25 Underperform
CAPS All Stars
 
31 Outperform
10 Underperform

How do you think Ligand Pharmaceuticals will perform against the market?



You pick for Ligand Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John L. Higgins, CEO

100% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Ligand Pharmaceuticals.

Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers